Eli Lilly Reports Omvoh Disease-Control Results in Ulcerative Colitis and Crohn’s

Lilly said one-year analyses from the LUCENT and VIVID programs found Omvoh met specified disease-control or remission endpoints in ulcerative colitis and Crohn’s disease. In ulcerative colitis, 27.7% of Omvoh-treated patients reached the composite endpoint versus 14% on placebo; in Crohn’s disease, 20.4% achieved corticosteroid-free deep remission versus 2% on placebo.